A dose-finding and pharmacokinetic study of the matrix metalloproteinase inhibitor MMI270 (previously termed CGS27023A) with 5-FU and folinic acid

Cancer Chemotherapy and Pharmacology

Volumn 55, Issue 1, 2005, Pages 39-46

  Eatock, M ^a,b   Cassidy, J ^c   Johnson, J ^c   Morrison, R ^a   Devlin, M ^a   Blackey, R ^a   Owen, S ^d   Choi, L ^d   Twelves, C ^a  

^a BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^b BELFAST CITY HOSPITAL   (United Kingdom)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

5 Fluorouracil; Antiangiogenesis; Chemotherapy; Metalloproteinase inhibition; Pharmacokinetics

Indexed keywords

CGS 27023A; FLUOROURACIL; FOLINIC ACID;

ADULT; AGED; ANOREXIA; ARTHRALGIA; ARTHROPATHY; ARTICLE; CLINICAL ARTICLE; COLORECTAL CANCER; CONJUNCTIVITIS; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG TOLERABILITY; FEASIBILITY STUDY; FEMALE; HUMAN; JOINT STIFFNESS; LETHARGY; MALE; MYALGIA; NAUSEA; PRIORITY JOURNAL; RASH; SIDE EFFECT; STOMATITIS; TOXICITY; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLONIC NEOPLASMS; DRUG INTERACTIONS; FEMALE; FLUOROURACIL; HUMANS; HYDROXAMIC ACIDS; LEUCOVORIN; MALE; METALLOENDOPEPTIDASES; MIDDLE AGED; PROTEASE INHIBITORS; PYRAZINES; RECTAL NEOPLASMS; SULFONAMIDES;

EID: 11244354290     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-004-0856-4     Document Type: Article

References (25)

1. Ahmann FR, Saad F, Mercier R, Huddart RA, Roberts JT, Collier M, Bettencourt L, Zhang MH, Clendeninn NJ, Wilding G (2001) Interim results of a phase III study of the matrix metalloprotease inhibitor prinomastat in patients having metastatic, hormone refractory prostate cancer (HRPC). Proc Am Soc Clin Oncol 20:174a
2. Amano S, Akutsu N, Matsunaga Y, Nishiyama T, Champliaud MF, Burgeson RE, Adachi E (2001) Importance of balance between extracellular matrix synthesis and degradation in basement membrane formation. Exp Cell Res 271:249-262
3. Bramhall SR, Hallissey MT, Whiting J, Scholefield J, Tierney G, Stuart RC, Hawkins RE, McCulloch P, Maughan T, Brown PD, Baillet M, Fielding JW (2002) Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Br J Cancer 86:1864-1870
4. Eskens FA, Levitt NC, Sparreboom A, Choi L, Mather R, Verweij J, Harris AL (2000) Effect of food on the pharmacokinetics of oral MM1270b (CGS27023a), a novel matrix metalloproteinase inhibitor. Clin Cancer Res 6:431-433
5. Evans JD, Stark A, Johnson CD, Daniel F, Carmichael J, Buckels J, Imrie CW, Brown P, Neoptolemos JP (2001) A phase II trial of marimastat in advanced pancreatic cancer. Br J Cancer 85:1865-1870
6. de Gramont A, Bosset JF, Milan C, Rougier P, Bouche O, Etienne PL, Morvan F, Louvet C, Guillot T, Francois E, Bedenne L (1997) Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 15:808-815
7. Hidalgo M, Eckhardt SG (2001) Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 93:178-193
8. Itoh T, Tanioka M, Yoshida H, Yoshioka T, Nishimoto H, Itohara S (1998) Reduced angiogenesis and tumor progression in gelatinase a-deficient mice. Cancer Res 58:1048-1051
9. Kleiner DEJ, Stetler-Stevenson WG (1993) Structural biochemistry and activation of matrix metalloproteinases. Curr Opin Cell Biol 5:891-897
10. Levitt NC, Eskens FA, O'Byrne KJ, Propper DJ, Denis LJ, Owen SJ, Choi L, Foekens JA, Wilner S, Wood JM, Nakajima M, Talbot DC, Steward WP, Harris AL, Verweij J (2001) Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023a), in patients with advanced solid cancer. Clin Cancer Res 7:1912-1922
11. Mackean MJ, Cassidy J, Jodrell DI, Paul J, Reed NS, Canney PA, Yosef H, Habeshaw T, Robertson AG, McInnes A, Twelves CJ (1998) Bolus/infusional 5-fluorouracil and folinic acid. A report on two prospective, consecutive phase II studies with 5-fluorouracil dose escalation. Br J Cancer 77:1480-1486
12. Matrissian LM (1992) The matrix-degrading metalloproteinases. Bioessays 14:455-463
13. Moore M, Hamm J, Eisenberg P, Dagenais M, Hagan K, Fields A, Greenberg B, Schwartz B, Ottaway J, Zee B, Seymour L (2000) A comparison between gemcitabine (gem) and the matrix metalloproteinase (mmp) inhibitor bay 12-9566 (9566) in patients (pts) with advanced pancreatic cancer. Proc Am Soc Clin Oncol 19:240a
14. Nemunaitis J, Poole C, Primrose J, Rosemurgy A, Malfetano J, Brown P, Berrington A, Cornish A, Lynch K, Rasmussen H, Kerr D, Cox D, Millar A (1998) Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies. Clin Cancer Res 4:1101-1109
15. Nguyen M, Arkell J, Jackson CJ (1998) Active and tissue inhibitor of matrix metalloproteinase-free gelatinase b accumulates within human microvascular endothelial vesicles. J Biol Chem 273:5400-5404
16. Primrose JN, Bleiberg H, Daniel F, Van Belle S, Mansi JL, Seymour M, Johnson PW, Neoptolemos JP, Baillet M, Barker K, Berrington A, Brown PD, Millar AW, Lynch KP (1999) Marimastat in recurrent colorectal cancer: exploratory evaluation of biological activity by measurement of carcinoembryonic antigen. Br J Cancer 79:509-514
17. Rosemurgy A, Harris J, Langleben A, Casper E, Goode S, Rasmussen H (1999) Marimastat in patients with advanced pancreatic cancer: a dose-finding study. Am J Clin Oncol 22:247-252
18. Smylie M, Mercier R, Aboulafia D, Tucker R, Bonomi P, Collier M, Keller MR, Stuart-Smith J, Knowles M, Clendeninn MJ, Shepherd F (2001) Phase III study of the matrix metalloprotease (mmp) inhibitor prinomastat in patients having advanced non-small cell lung cancer (nsclc). Proc Am Soc Clin Oncol 20:307a
19. Talbot DC, Brown PD (1996) Experimental and clinical studies on the use of matrix metalloproteinase inhibitors for the treatment of cancer. Eur J Cancer 32A:2528-2533
20. Trotti A, Byhardt R, Stetz J, Gwede C, Corn B, Fu K, Gunderson L, McCormick B, Morrisintegral M, Rich T, Shipley W, Curran W (2000) Common toxicity criteria: version 2.0 an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys 47:13-47
21. Wattanatorn W, McLeod H, Cassidy J, Kendle K (1997) High-performance liquid cromatographic assay of 5-fluorouracil in human erythrocytes, plasma and whole blood. J Chromatogr B Biomed Sci Appl 692:233-237
22. WHO (1979) WHO handbook for reporting results of cancer treatment. WHO offset publication no. 48. World Health Organization, Geneva
23. Wojtowicz-Praga S, Dickson R, Hawkins M (1997) Matrix metalloprotease inhibitors. Invest New Drugs 15:61-75
24. Wood J, Schnell C, Cozens R (1998) CGS27023a, a potent and orally active matrix metalloprotease inhibitor with anti-tumour activity. Proc Am Assoc Cancer Res 39:83a
25. Zucker S, Mirza H, Conner CE, Lorenz AF, Drews MH, Bahou WF, Jesty J (1998) Vascular endothelial growth factor induces tissue factor and matrix metalloproteinase production in endothelial cells: conversion of prothrombin to thrombin results in progelatinase a activation and cell proliferation. Int J Cancer 75:780-786